Positive 3-year results from the phase III PHOTON study were presented at the recent American Academy of Ophthalmology (AAO) ...

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...

Fuludu said as much during the flag off of the 2024 Delta Ethnic Peace and Unity Cup, being organized by the Centre for Peace ...

Cohort receiving 150,000 cells achieved 11-letter mean change in best corrected visual acuity (BCVA) at 6 months, ...

Diabetes is a widespread condition that can lead to serious health issues when not managed well. One of the most concerning ...

Two papers published in Journal of Orthopaedic Research Spine show the promise of PP353 through preclinical development and ...

Opuviz, which references Regeneron Pharmacueticals’ vision loss inhibitor Eylea, treats wet age-related macular degeneration, ...

The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...

Diabetic retinopathy (DR) is the primary cause of visual impairment among working-age populations in industrialized nations.

The AI model, dubbed BiomedParse, uses OpenAI's GPT-4 and can examine CT scans, MRIs, X-ray images, ultrasounds, and more.

A nasal spray would be a workaround for drug resistance seen with oral diuretics, with the potential to reduce hospital ...

Tryvio TM (aprocitentan) is now available for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure (BP) in adult patients who are not adequately ...